Article citationsMore>>

Abe, K., Itoh, M. and Asahina, A. (2019) Rituximab‐Induced Vasculitis: Does the Immune Complex of Rituximab Play a Key Role in Developing Paradoxical Adverse Events? The Journal of Dermatology, 46, e311-e312.
https://doi.org/10.1111/1346-8138.14872

has been cited by the following article:

• TITLE: Rituximab Induced Vasculitis: Dose the Antigen-Antibody Complex of Rituximab Play a Role in Developing Leukocytoclastic Vasculitis?—A Case Report and Review of the Literature

  AUTHORS: Ahmed A. AlTaroti, Zahra Z. AlZahir, Salah Abohelaika

  KEYWORDS: Rheumatoid Arthritis, Rituximab, Vasculitis, Leukocytoclastic Vasculitis

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.9, September 11, 2024

  ABSTRACT: Rituximab is a monoclonal antibody that targets CD20, which is a specific B-cell surface antigen. It was the first monoclonal antibody that was approved for the treatment of non-Hodgkin lymphoma, rheumatoid arthritis, and other cutaneous lymphoid malignancies. There are many off-label uses of rituximab, such as systemic lupus erythematosus, autoimmune hemolytic anemia, multiple sclerosis, graft-versus-host disease, chronic lymphocytic leukemia, and chronic immune-mediated thrombocytopenia. Among the rare side effects associated with rituximab treatment is vasculitis, more specifically, leukocytoclastic vasculitis. Here, we describe a 21-year-old Saudi female with leukocytoclastic vasculitis occurring three months after treatment with rituximab.